{"id":10,"date":"2015-08-11T16:26:03","date_gmt":"2015-08-11T16:26:03","guid":{"rendered":"http:\/\/www.canadianinstitute.com\/event-template\/?page_id=10"},"modified":"2021-10-18T20:39:15","modified_gmt":"2021-10-18T20:39:15","slug":"overview","status":"publish","type":"page","link":"https:\/\/www.americanconference.com\/life-sciences-antitrust\/","title":{"rendered":"Overview"},"content":{"rendered":"
\r\n
\r\n
\r\n\r\n
\r\n
\r\n \"\"\r\n <\/div>\r\n
\r\n

On-Demand Recording<\/strong><\/h3>\r\n

Missed ACI’s Premier Conference on Life Sciences Antitrust<\/strong>? Purchase the recording and access information delivered by our esteemed faculty of antitrust enforcers, leading in-house counsel, and law firm attorneys from wherever you may be.<\/p>\r\n Learn More<\/a>\r\n <\/div>\r\n <\/div>\r\n\r\n <\/div>\r\n <\/div>\r\n<\/div>\r\n\r\n

\r\n
\r\n

* Pay-for-Delay Lawsuits * Price Fixing Investigations *
\r\n * M&A Scrutiny in the U.S. and Abroad *
\r\n * New Antitrust Enforcement Policies *<\/strong> <\/h2>\r\n <\/div>\r\n<\/div>\r\n
\r\n
\r\n

Now more than ever, life sciences companies must remain abreast of the emerging enforcement trends as well as the government\u2019s antitrust analysis for evaluating anticompetitive behavior.<\/strong><\/p>\r\n\t \r\n

As we proceed through 2021, the spotlight on antitrust activity in the life sciences industry shines brighter than ever. For several years, state and federal antitrust enforcers in the U.S. and even international antitrust and competition authorities have been watching the life sciences industry closely for anticompetitive activity. The Biden Administration is now forming its new competition policy and there is pending antitrust legislation which will unquestionably affect the life sciences industries. At the same time, the U.S. DOJ has just confirmed that they are developing new policies to prevent patents from being used as tools for anticompetitive practices, a recent series of criminal antitrust investigations have been brought by federal and state authorities alleging generic price fixing collusion, and a novel multinational task force has just been put in place to examine the anticompetitive impact of life sciences M+A activity. All of these new changes are raising life sciences antitrust concerns to an all-time high, and could significantly increase the volume of litigation for IP and antitrust trial lawyers and their clients.<\/p>\r\n\r\n

That is why you do not want to miss the chance to attend\u00a0the only event on the market where you can hear from antitrust enforcers, leading in-house counsel, and\u00a0 law firm attorneys<\/strong>\u00a0on how to successfully tackle the most complex antitrust challenges currently facing biopharmaceutical manufacturers.<\/p>\r\n <\/div>\r\n<\/div>\r\n\r\n

\r\n
\r\n
Distinguished Conference Co-Chairs<\/span><\/span><\/h6>\r\n\r\n
\r\n
\r\n
\r\n \"Speaker\r\n

Ian R. Conner<\/strong><\/h4>\r\n

Partner<\/em>
Latham & Watkins LLP<\/strong>
(Former Director of the FTC Bureau of Competition, 2019-2021)<\/em><\/p>\r\n <\/div>\r\n <\/div>\r\n

\r\n
\r\n \"Speaker\r\n

Debbie Feinstein<\/strong><\/h4>\r\n

Partner<\/em>
Arnold & Porter Kaye Scholer LLP<\/strong>
(Former Director of the FTC Bureau of Competition, 2013-2017)<\/em><\/p>\r\n <\/div>\r\n <\/div>\r\n<\/div>\r\n\r\n <\/div>\r\n<\/div>\r\n\r\n

\r\n
\r\n

Leading antitrust counsel will participate in discussions and provide analysis on:<\/strong><\/p>\r\n